Autopsy report · NCT06572189
The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Cause of deathOther
“Based on the results of another intravenous injection therapy CD-801 for the treatment of hepatocellular carcinoma, we have decided to change the administration method and therefore withdraw this trial protocol.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Early Phase 1
- Sponsor
- Shanghai Changzheng Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)
- Participants
- 0
- Sites
- 1
- Countries
- China
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.